GlassScriptPhysician profile
Felipe Diaz
NPI 1568431799
$6,924.28
in general payments reported to CMS, 2019-2025
41 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $1,643 · 2023: $1,745 · 2024: $1,803 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,905.84 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $833.59 | 2021-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbott Laboratories | $795.31 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $719.48 | 2022-2025 | |
| Abbvie INC. | $618.05 | 2021-2025 | Mavyret, Ubrelvy, Vraylar |
| Novo Nordisk INC | $542.58 | 2021-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $447.97 | 2022-2025 | Yeztugo, Epclusa |
| Astrazeneca Pharmaceuticals LP | $394.74 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Ardelyx, INC. | $222.40 | 2025 | Ibsrela |
| Astellas Pharma US INC | $194.76 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $192.22 | 2023-2024 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $173.67 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $142.27 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $127.02 | 2022-2024 | Rexulti |
| Shield Therapeutics INC | $122.18 | 2023-2025 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $119.74 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.